Sandoz Group AG | WebDisclosure

Basculer en Français

9992	Companies
202683	Keywords
133294	Articles
107628	Press releases

Home
Companies
Sandoz Group AG

PRESS RELEASE

published on 12/01/2025 at 07:00, 3 months 6 days ago

Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment options for cancer-related bone disease and osteoporosis. The European launch marks a key milestone in Sandoz's growth strategy

Europe Biosimilars Cancer Osteoporosis Sandoz
BRIEF

published on 11/24/2025 at 07:05, 3 months 13 days ago

Sandoz lance Afqlir® en Europe pour le traitement des maladies rétiniennes

Biosimilaires Maladies De La Rétine Sandoz Lancement En Europe Afqlir®
BRIEF

published on 11/24/2025 at 07:05, 3 months 13 days ago

Sandoz Launches Afqlir® in Europe for Retinal Diseases

Biosimilars Retinal Diseases Sandoz Europe Launch Afqlir®
PRESS RELEASE

published on 11/24/2025 at 07:00, 3 months 13 days ago

Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases. Afqlir® matches reference medicine in efficacy, safety, and pharmacokinetics, reinforcing Sandoz commitment to patient access

Retinal Diseases Sandoz Aflibercept Afqlir European Launch
BRIEF

published on 11/17/2025 at 07:05, 3 months 20 days ago

Sandoz lance le premier biosimilaire de la sclérose en plaques, TYRUKO®, aux États-Unis.

Sclérose En Plaques Biosimilaire Sandoz TYRUKO® Natalizumab
BRIEF

published on 11/17/2025 at 07:05, 3 months 20 days ago

Sandoz Launches First MS Biosimilar TYRUKO® in US

Multiple Sclerosis Biosimilar Sandoz TYRUKO® Natalizumab
PRESS RELEASE

published on 11/17/2025 at 07:00, 3 months 20 days ago

Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz launches TYRUKO® (natalizumab-sztn) in US, the first and only multiple sclerosis biosimilar, offering cost-effective treatment. TYRUKO® approved for all indications of reference medicine Tysabri®

US Market Multiple Sclerosis Biosimilar Sandoz TYRUKO
BRIEF

published on 11/12/2025 at 07:40, 3 months 25 days ago

Sandoz Secures Global License for Breast Cancer Biosimilar

Oncology Biosimilar Breast Cancer Sandoz Pertuzumab
BRIEF

published on 11/12/2025 at 07:40, 3 months 25 days ago

Sandoz obtient une licence mondiale pour un biosimilaire du cancer du sein

Oncologie Biosimilaire Cancer Du Sein Sandoz Pertuzumab
PRESS RELEASE

published on 11/12/2025 at 07:35, 3 months 25 days ago

Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz signs global license agreement with EirGenix Inc. to commercialize biosimilar pertuzumab for HER2-positive breast cancer treatment, reinforcing its position in oncology

Agreement Biosimilar Breast Cancer Sandoz Pertuzumab

Accesswire

Published on 03/07/2026 at 00:00, 7 hours 47 minutes ago

Green Bridge Metals to Ship Titac Drill Core for Metallurgical Testing to Evaluate Titanium Dioxide Extraction Potential
Published on 03/06/2026 at 22:30, 9 hours 17 minutes ago

Sceptre Ventures Announces Amendment and Closing of Private Placement Offering
Published on 03/06/2026 at 22:00, 9 hours 47 minutes ago

Pegasus Resources Inc. Announces Annual General and Special Meeting of Shareholders
Published on 03/06/2026 at 17:55, 13 hours 52 minutes ago

High Tide Resources Announces Upsize to Private Placement
Published on 03/06/2026 at 14:00, 17 hours 47 minutes ago

CHAR Technologies Announces Increase to C$ 3.97M and Closing of Book on Previously Announced Private Placement

View all ACCESSWIRE

EQS Group

Published on 03/07/2026 at 02:03, 5 hours 44 minutes ago

EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Published on 03/06/2026 at 23:05, 8 hours 42 minutes ago

DeFi Technologies Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Published on 03/06/2026 at 19:30, 12 hours 17 minutes ago

TRADE SHOWS: IEG, OUTSTANDING RESULTS FOR KEY - THE ENERGY TRANSITION EXPO WITH +10% TOTAL VISITORS AND +9% FROM ABROAD
Published on 03/06/2026 at 18:44, 13 hours 2 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/06/2026 at 18:30, 13 hours 17 minutes ago

WHO Foundation announces collaboration with Lilly to strengthen health systems for obesity care

Les Echos

Published on 03/06/2026 at 18:05, 13 hours 42 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 28/02/2026
Published on 03/06/2026 at 18:05, 13 hours 42 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 28/02/2026
Published on 03/06/2026 at 18:00, 13 hours 47 minutes ago

Outstanding shares and voting rights statement at 28 February 2026
Published on 03/06/2026 at 18:00, 13 hours 47 minutes ago

Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 28 février 2026
Published on 03/06/2026 at 18:00, 13 hours 47 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 27 février 2026

View all LES ECHOS COMFI WIRE